Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 708 across all filing types
Latest filing 2026-02-13 Legal Proceedings Report
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Podsumowanie spotkania z Food and Drug Administration, (FDA) typu B dla CPL'36, w leczeniu dyskinez indukowanych lewodopą u pacjentów z chorobą Parkinsona (PD-LID). - Content (PL)
Legal Proceedings Report Classification · 1% confidence The document is a regulatory announcement from Celon Pharma S.A. regarding feedback received from the U.S. Food and Drug Administration (FDA) concerning the clinical development plan for a specific drug (CPL'36). It details the regulatory interaction, the FDA's stance on clinical trial design, and the company's future plans based on this feedback. Since it is a formal regulatory update regarding clinical trial progress and regulatory interaction that does not fit into specific categories like M&A, dividends, or financial reports, it is classified as a Regulatory Filing (RNS).
2026-02-13 Polish
Terminy publikacji raportów okresowych w 2026 roku - Content (PL)
Report Publication Announcement Classification · 1% confidence The document is a short announcement from Celon Pharma S.A. detailing the scheduled dates for the publication of their periodic reports (annual and quarterly) for the year 2026. It does not contain the actual financial reports themselves, but rather serves as a notification of the reporting calendar. According to the 'Menu vs Meal' rule, an announcement regarding the timing of future report releases is classified as a Report Publication Announcement (RPA).
2026-01-26 Polish
Raport 3 kwartał 2025
Regulatory Filings
2025-11-19 Polish
Statut - tekst jednolity
Audit Report / Information Classification · 1% confidence The document is a 'Statut Spółki' (Company Articles of Association) for Celon Pharma S.A. It outlines the company's general provisions, business activities, capital structure, and the governance roles of the Board, Supervisory Board, and General Meeting. Such documents are fundamental corporate governance filings that define the legal framework of the entity. In the provided classification schema, 'Governance Information' (CGR) is the most appropriate category for documents detailing internal rules, board structure, and governance practices. FY 2025
2025-10-10 Polish
Rejestracja zmiany Statutu Spółki - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement from Celon Pharma S.A. informing the market about the registration of changes to the company's Articles of Association (Statute) by the District Court. It details the specific amendment regarding the Supervisory Board's duties and mentions that the consolidated text of the Statute is attached. Since this is a formal regulatory notification regarding corporate governance and statutory changes, and does not fit into specific categories like financial reports or director dealings, it is classified as a general regulatory filing.
2025-10-10 Polish
Zawarcie przez spółkę zależną umowy z generalnym wykonawcą inwestycji - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement from Celon Pharma S.A. regarding the signing of a significant construction contract for a new production facility in Slovakia. It details the nature of the agreement, the contractor, the strategic importance, the financial value (63.3 million PLN), and penalty clauses. Since this is a specific corporate event announcement that does not fit into categories like M&A, financial reporting, or share transactions, it falls under the general regulatory filing category.
2025-10-03 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.